Piramal Consumer Healthcare posts mid-to-high-teens growth in Q1 FY27
Piramal Pharma said its Consumer Healthcare business grew in the mid-to-high teens in Q1 FY27, supported by power brands, e-commerce, broader distribution, premiumisation and continued brand investment.
Piramal Pharma reported Q1 FY27 mid-to-high teens revenue growth and EBITDA-margin expansion across its businesses. Consumer Healthcare growth was driven by power brands, e-commerce, wider distribution, premiumisation and brand investment.
Why this matters
No related recent signals were provided, so Q1 FY27 Consumer Healthcare growth establishes the current reference point for Piramal Pharma Limited.
Retail-company signals are accelerating, up 308350% QoQ.